May 19,2021

Amalgam Rx Acquires Adaptive, Conversational, Artificial Intelligence (AI) Assets

Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform, is announcing the acquisition of the assets of Geetha, LLC, an adaptive, conversational AI company. With this transaction, Amalgam acquires Geetha’s turnkey psychosocial engine (personality, moods, motivators, etc.) in 40 languages, algorithms to collect contextual data via chat, AI-based chat model and platform to create low-no code virtual personalized agents, motivational content, common sense ontology for a rich understanding of a user’s life, and learning algorithms to respond to interactions and improve intervention framework.

COLLABORATION MERGERS & ACQUISITION

#product & service

View Analyst & Ambassador Comments
Go to original news
Jun 16,2021

Amalgam Rx Receives CE Mark for Basal Insulin Titration

Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform, is announcing it has achieved the Conformité Européenne (CE) Mark for its insulin titration application, iSage RxTM and its white-labeled variants. With this CE Mark, iSage Rx’s capacity to support the titration of all basal insulins and enable connectivity to the leading Bluetooth-enabled blood glucose meters from Roche, Lifescan, and Ascensia, is now cleared for the European market.

REGULATORY CE MARK

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 01,2022

Amalgam Rx’s DoseCheck Receives SFDA Clearance in Saudi Arabia

Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform, announced that its insulin titration solution, DoseCheck, will now help patients and their care teams manage their insulin and glucose in yet another country.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 21,2023

Lark Health’s Artificial Intelligence (AI) Heart Health Program Significantly Improves Cardiac Self-Efficacy

Lark Health, a leading digital care company for the prevention and management of chronic conditions, today announced key results from its pilot study surrounding its Artificial Intelligence (AI)-powered Heart Health program, which helps patients prevent and manage heart disease by targeting Cardiovascular Disease (CVD) risk factors. The study, “Cardiac Self-Efficacy Improvement in a Digital Health Pilot Program for Heart Health” found that, on average, study participants increased their Cardiac Self-Efficacy (CSE) score by 12.93 percent, the first digital care solution to show CSE improvement. In collaboration with Roche Diagnostics, the 90-day pilot study first helped participants identify their own personal risks for developing cardiovascular disease, and then provided them with AI-powered care coaching and educational lessons focused on behaviors that reduce those risks and promote better heart health. The CSE study results will be presented at The Society of Behavioral Medicine's 44th Annual Meeting & Scientific Sessions in Phoenix, AZ, from April 26–29, 2023.

CLINICAL STUDY

#coaching

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 04,2023

Insulet Reports First Quarter 2023 Revenue Increase of 21% Year-Over-Year

Insulet Corporation today announced financial results for the three months ended March 31, 2023. First quarter 2023 revenues were reported as $358.1 million, up 21.2%, or 23.3% in constant currency, compared to $295.4 million in the prior year. Total Omnipod revenues were $357.6 million, an increase of 32.7%, or 34.9% in constant currency. “Our first quarter results demonstrate strong financial performance, including unprecedented results for U.S. Omnipod, and ongoing strategic progress,” said Jim Hollingshead, President and Chief Executive Officer. “Omnipod 5 is quickly transforming diabetes management in the U.S. by offering improved outcomes and quality of life and we remain on track to begin our staged international roll-out in a matter of months. We expect 2023 to be another successful year as we build on our momentum and further execute our mission to improve the lives of people with diabetes.”

View Analyst & Ambassador Comments
Go to original news
May 10,2023

Dexcom Showcases Accuracy, Reliability and Ease of Use of Its Dexcom G6 CGM System at the 66th Annual Meeting of the Japan Diabetes Society

DexCom will showcase the accuracy, reliability and ease of use of its Dexcom G6 CGM System and will highlight the latest clinical evidence that continues to demonstrate the effectiveness of Dexcom CGM during the 66th Annual Meeting of the Japan Diabetes Society held May 11-13, 2023 in Kagoshima, Japan.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
May 11,2023

DarioHealth Reports First Quarter Financial and Operating Results

DarioHealth today reported financial results for the first quarter 2023 and provided a corporate and commercial update. Revenues for the first quarter ended March 31, 2023 were $7.07 million, a 12.3% decrease from $8.06 million for the first quarter ended March 31, 2022, and an increase of 3.8% from $6.8 million for the fourth quarter of 2022. The decrease in revenues for the quarter ended March 31, 2023 as compared to the quarter ended March 31, 2022 resulted mainly from lower revenues from the Company's Business-to-Consumer (B2C) Channel. "Business-to-Business (B2B) revenues continued to increase, representing approximately 70% of our total revenue during the first quarter, up from 56% in the first quarter of 2022.'' said the CEO of DarioHealth Erez Raphael.

View Analyst & Ambassador Comments
Go to original news
May 09,2023

Glooko Unveils Redesigned Mobile App

Glooko, Inc., today announced the redesign of their award-winning mobile app for its connected care platform, that will provide a more streamlined experience for its mobile users. The enhancements include a new mobile app design that makes it easier for users to organize their data in one place and share with their HCPs; and it hosts Glooko's upcoming functionality of 'Precision Engagement.' Precision Engagement tools leverage environmental, behavioral, and physiologic data from medical devices, wearables, consumer devices, and smartphones to better understand an individual's unique preferences, habits, and environment.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 04,2023

Beta Bionics Appoints Dr. Steven Russell as Chief Medical Officer in Preparation for the Commercial Launch of the iLet Bionic Pancreas System

Beta Bionics announced the appointment of Steven Russell, MD, PhD, to the role of Chief Medical Officer as the company prepares for commercial launch of the iLet Bionic Pancreas System. Dr. Russell is an endocrinologist and diabetologist with 20 years of experience managing diabetes. He is an Associate Professor of Medicine at Harvard Medical School and an attending physician at Massachusetts General Hospital (MGH) Diabetes Associates in Boston where he has maintained a clinical practice managing diabetes in the outpatient and inpatient settings. Dr. Russell will retain his Harvard Medical School faculty appointment and will maintain his medical practice on a part-time basis at MGH Diabetes Associates.

View Analyst & Ambassador Comments
Go to original news
May 09,2023

Senseonics Holdings, Inc. Reports First Quarter 2023 Financial Results

Senseonics Holdings today reported financial results for the quarter ended March 31, 2023. Total revenue for the first quarter of 2023 was $4.1 million compared to $2.5 million for the first quarter of 2022. U.S. revenue was $2.1 million in the first quarter of 2023 compared to $0.8 million in the prior year period, and revenue outside the U.S. was $2.0 million in the first quarter of 2023 compared to $1.7 million in the prior year period. Senseonics reiterates the expectation for full year 2023 global net revenue to be in the range of $20 million to $24 million.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES